Express News | Hubei Biocause Pharmaceutical: CHINA BEST Life Insurance's cumulative original insurance premium income for January to February is approximately 8.035 billion yuan.

BreakingsMar 14 17:07

Express News | The financial Sector continues to explode, with Hubei Biocause Pharmaceutical and several other stocks hitting the daily limit.

BreakingsMar 14 11:01

Hubei Biocause Pharmaceutical (000627.SZ): has not yet repurchased company shares.

Glory Financial reported on March 3rd that Hubei Biocause Pharmaceutical (000627.SZ) announced that as of the close on March 3, 2025, the company's stock price was 3.88 yuan per share, exceeding the upper limit of the company's stock repurchase price. The company has cumulatively repurchased 0 shares through a designated securities account for stock repurchase via centralized bidding, which accounts for 0.00% of the company's current total share capital.

Gelonghui FinanceMar 3 16:38

Express News | Hubei Biocause Pharmaceutical: CHINA BEST Life Insurance's original insurance premium income in January 2025 is approximately 4.936 billion yuan.

BreakingsFeb 14 16:27

Major financial stocks fell in early trading: Hubei Biocause Pharmaceutical dropped over 5%, ChinaLin fell by 4%.

On January 24, according to Gelonghui, most major financial stocks fell in the morning. Hubei Biocause Pharmaceutical dropped over 5%, ChinaLin, which had The Rise and Stop Yesterday, fell by 4%, with China Life Insurance, Hua Xia Bank, China Everbright Bank, MINSHENG BANK, and Bank of Shanghai also declining.

Gelonghui FinanceJan 24 09:47

Express News | Hubei Biocause Pharmaceutical: Stocks trading has abnormal fluctuations, currently there are no significant matters that should be disclosed but are not disclosed.

BreakingsJan 23 18:14